|
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
Travel, Accommodations, Expenses - BeiGene |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BeiGene |
Research Funding - BeiGene |
Travel, Accommodations, Expenses - BeiGene |
|
|
No Relationships to Disclose |